USFDA flags purified talc at Zydus's Baddi plant in Warning Letter
The agency cites a raw-materials failure in a technical review, not a live inspection. The facility already carries a less severe FDA classification.
— 1 earlier story on Zydus Lifesciences Ltd. →What's new
- USFDA issued a Warning Letter for the Baddi plant, citing purified talc that failed USP standards.
- The finding came from a technical review, not an on-site inspection.
- Zydus says operations and supplies from Baddi are unaffected and will remediate within the FDA's timeline.
Why this matters
A Warning Letter is a formal regulatory step that can lead to import restrictions if the FDA rejects the company's corrective plan. The issue is narrow—raw-materials—but it lands on a site already flagged with a Voluntary Action Indicated classification from its August 2025 inspection. Two FDA flags at one facility in under a year changes the risk profile for any pending approvals routed through Baddi.
What we're watching
- Zydus's formal remediation response and the timeline the FDA sets for it.
- Whether the FDA escalates the site's classification or moves toward an import alert.
- The impact on pending ANDA approvals and product supplies using the Baddi facility.
The full read
The USFDA has issued a Warning Letter to Zydus Lifesciences for its Baddi formulation plant. The agency's concern is purified talc that failed to meet USP standards. This is not a finding from a walk-through. It came from a technical review of documents. The Baddi site already carries a Voluntary Action Indicated classification from its last on-site inspection in August 2025. Zydus says it's fixing the problem within the FDA's timeline and that business continues uninterrupted. That claim is conditional. Warning Letters become binding only after the company submits a remediation plan the FDA accepts. If the agency rejects it, the next step is a potential import alert that would freeze product shipments from this facility into the US. The talc issue may be narrow. But its timing is not. It compounds an existing regulatory flag at the same site.
Questions answered
- What specific raw material did the FDA flag?
- The Warning Letter cites purified talc that did not meet current United States Pharmacopeia (USP) requirements. This is a technical observation related to a material input used in manufacturing.
- Was this finding from a live plant inspection?
- No. The observations stemmed from a paper-based technical review. The Baddi facility's last physical FDA inspection was in August 2025, which resulted in a Voluntary Action Indicated classification.
- Does the Warning Letter halt production or shipments?
- Zydus states that current operations and supplies from the Baddi facility are not affected. The company has committed to completing remediation steps within the FDA's stipulated timelines.
- Why is this Warning Letter significant for the site?
- It is the second major FDA flag at the same facility in under a year. The Baddi plant already carries a Voluntary Action Indicated classification from its August 2025 inspection. Two regulatory actions at one site increase scrutiny on any future approvals or inspections.
Story so far
All notes on ZYDUSLIFE →- 3 Jun 2026 · 10:33 AM IST USFDA flags purified talc at Zydus's Baddi plant in Warning Letter
- 7d ago Zydus's US liver drug gets a faster FDA look. A decision comes Nov 2026.